The GLP-1 receptor agonist has been considered in shortage since 2022, but the FDA confirmed with manufacturers that presented and projected demand can now be met.
Obesity has many implications for injured workers, from being a catalyst for injuries to increasing healthcare costs and lengthening time away from work.
